IPP Bureau
NVIDIA & Eli Lilly launch $1 billion AI Lab to reinvent drug discovery
By IPP Bureau - January 13, 2026
AbbVie strikes deal with Trump administration on drug prices, US investment
By IPP Bureau - January 13, 2026
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment
By IPP Bureau - January 12, 2026
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Pfizer’s BRAFTOVI combo shows breakthrough results in aggressive colorectal cancer
By IPP Bureau - January 12, 2026
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Aragen slashes drug development time with CHOMax platform
By IPP Bureau - January 12, 2026
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
4Moving Biotech bags FDA nod to launch US trial of groundbreaking osteoarthritis therapy
By IPP Bureau - January 12, 2026
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment
By IPP Bureau - January 12, 2026
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy
By IPP Bureau - January 12, 2026
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
PharmaForceIQ acquires Aktana, launches first “optichannel-in-a-box” platform for pharma
By IPP Bureau - January 12, 2026
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
FDA rejects Vanda’s jet lag drug in current form
By IPP Bureau - January 12, 2026
Vanda strongly disputes the FDA’s reasoning
Evotec subsidiary bags Gates Foundation grant to expand global access to biologics
By IPP Bureau - January 12, 2026
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
Organon strikes deal with Daiichi Sankyo to launch breakthrough cholesterol drug in Northern Europe
By IPP Bureau - January 12, 2026
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
NAMSA expands US footprint with Labcorp medical device testing acquisition
By IPP Bureau - January 12, 2026
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
Alembic announces USFDA tentative approval for Bosutinib tablets
By IPP Bureau - January 12, 2026
Diabeloop bags FDA nod for DBLG2, opens US market for automated insulin delivery
By IPP Bureau - January 12, 2026
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
